Immunovant, Inc.
IMVT
$15.80
-$0.06-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.58% | -57.20% | -26.54% | -11.46% | -22.93% |
| Total Depreciation and Amortization | 63.20% | 50.23% | 37.26% | 27.72% | 19.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.45% | 19.16% | 20.24% | 22.92% | 26.38% |
| Change in Net Operating Assets | -557.10% | 232.58% | -33.54% | -140.78% | 124.25% |
| Cash from Operations | -75.46% | -54.50% | -29.59% | -43.19% | -13.83% |
| Capital Expenditure | -110.83% | -200.00% | -224.63% | -148.50% | -82.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -110.83% | -200.00% | -224.63% | -148.50% | -82.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -4.94% | -98.86% | 563.42% | 563.98% | 572.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.69% | 100.00% | -2,110.29% | -2,110.29% | -2,110.29% |
| Cash from Financing | -3.80% | -98.85% | 557.57% | 558.11% | 566.47% |
| Foreign Exchange rate Adjustments | -24.77% | 277.97% | 21.02% | 45.50% | 351.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -69.63% | -222.42% | 249.44% | 336.56% | 320.69% |